FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110631704> ?p ?o ?g. }

• W2110631704 endingPage "12" @default.
• W2110631704 startingPage "10" @default.
• W2110631704 abstract "HIV and Mycobacterium tuberculosis are important pathogens leading to persistent infection in humans. The majority of HIV-infected patients progress to AIDS. Only about 10% of patients are non-progressors and remain free of AIDS for many years. In contrast, most subjects infected with M. tuberculosis will remain free of disease and only 5–10% will develop clinical tuberculosis (TB). Markers of disease activity are needed to evaluate disease progression and to monitor response to therapy. A number of serological markers of disease activity have been studied in HIV and M. tuberculosis-infected patients. They are generally referred to as markers of immune activation. This state of immune activation reflects a complex host response to the pathogens and could play an important role in the pathogenesis of the disease. The pattern of serological markers of immune activation could vary according to the pathogen. Markers discriminating co-pathogens would be particularly useful for the monitoring of HIV infection. In this issue, Lawn et al. present data suggesting that soluble tumour necrosis factor receptor type 1 (sTNF-RI) and β2-microglobulin (β2-M) could be used as independent markers of disease activity in TB and HIV infection, respectively.Patients with HIV infection have elevated serum concentrations of a number of markers of immune activation. Some of these markers, including β2-M, neopterin, soluble IL-2 receptor and sTNF-RII, have been shown to have prognostic significance [1–5]. Lederman et al. recently suggested that sTNF-RII is the marker of immune activation most independently correlated with HIV viral load [6]. In developing countries where CD4 count and viral load can often not be assessed, serological markers of immune activation could represent an affordable alternative to monitor disease progression and to assist management of patients. In addition, these molecules could also provide unique information about disease activity. Data reported by Salazar-Gonzalez et al. indicate that immune activation precedes, sometimes by several years, the increase in viral load and the loss of CD4 lymphocytes [7]. This observation supports the concept that immune activation plays a role in the pathogenesis of AIDS. Immune activation could accelerate disease progression by stimulating viral replication and by inducing apoptosis of T lymphocytes. Michel et al. reported that serum concentrations of β2-M are correlated with apoptosis of CD4 and CD8 lymphocytes in patients with HIV-1 or HIV-2 infection [8]. Moreover, patients with HIV-2 infection who have slower disease progression compared with patients with HIV-1 infection also show lower immune activation and lymphocyte apoptosis [8]. The TNF pathway could play an important role in disease progression. The interaction between TNF-α and the TNF-RII mediates the apoptosis of CD8 lymphocytes induced by HIV [9]. TNF-α was shown either to stimulate HIV replication through its interaction with TNF-RI or to inhibit viral replication through TNF-RII [10]. The preferential increase in the serum concentration of sTNF-RII compared with sTNF-RI in HIV-infected patients [3,11] (Lawn et al., this issue) could be related to the role played by sTNF-RII in the control of HIV replication and death of CD8 cells [10,12]. Another marker of immune activation which could play an important role in the pathogenesis of AIDS is IL-16. IL-16 is a ligand for CD4 and was shown to inhibit HIV replication [13,14]. Amiel et al. reported that serum IL-16 concentrations are elevated in patients with asymptomatic HIV infection and decrease with disease progression [13]. The combination of markers of immune activation that are up-regulated or down-regulated during disease progression could increase their prognostic significance. The monitoring of HIV infection requires markers that are not directly stimulated by co-pathogens. Data reported in this issue by Lawn et al. indicate that the serum concentration of β2-M is not influenced by TB in HIV-infected patients. Prospective studies are needed to confirm this observation and to evaluate the effect of other co-infections on the serum concentrations of β2-M and other markers of immune activation [15–18]. The relative stability of serum concentrations of β2-M further supports its potential interest in the monitoring of HIV infection [19]. Another important use of serological markers in HIV-infected patients could be the monitoring of anti-retroviral therapy [20,21].Little is known about the effect of primary M. tuberculosis infection on markers of immune activation. Data reported by Juffermans et al. indicate that contacts of TB cases have elevated serum concentrations of sTNF-RII, and to a lesser extent sTNF-RI [22]. As for HIV, the initial immune response could determine the ability of the host to control the infection with M. tuberculosis. Serological markers of immune activation could be useful in the identification of individuals at higher risk of developing TB and who would benefit from anti-mycobacterial chemotherapy. TB disease is associated with the increase of a number of soluble markers of immune activation [22–27]. As in HIV infection, this immune activation is associated with a state of immunosuppression [24]. Compared with healthy contacts, TB patients have defective interferon-gamma (IFN-γ) responses and increased apoptosis of CD4 lymphocytes [28]. Recent data obtained in mice suggest that the increased apoptosis of CD4 cells is a consequence of immune activation and is dependent on IFN-γ[29]. Other molecules, like TNF-α, could also be involved. IFN-γ plays a central role in the defence against mycobacteria [30]. Its suppression in TB patients could therefore play an important role in the pathogenesis of the disease. In contrast to HIV infection, patients with TB have high serum concentrations of sTNFR-1 [22] (Lawn et al., this issue). Interestingly, among patients with leprosy, elevated serum concentrations of sTNF-RI were only observed in subjects with lepromatous leprosy and type II reactions to therapy [31]. This suggests that during mycobacterial infections, the shedding of sTNF-RI is associated only with some types of immune responses. The shedding of sTNRs is induced by TNF-α and their serum concentrations could therefore reflect TNF-α bioactivity [32]. In soluble form, sTNF-Rs can neutralize or stabilize the bioactivity of TNF-α[32]. Among the other markers of disease activity in TB, IgE could be of special interest. Adams et al. recently reported that in patients with TB, therapy is associated with a reduction of serum IgE concentrations [33]. These data suggest that TB is associated with a T helper type 2 (Th2) response and that markers of Th2 activity could be useful in the monitoring of the disease. Other markers of immune activation have been studied in TB patients under anti-mycobacterial therapy. Some markers were found to be rapidly modulated by therapy but others remain elevated for several months [22,26,27,34].Prospective studies are needed to evaluate markers that could be specifically associated with HIV infection, tuberculosis or infection with other co-pathogens. Standardized quality control of laboratory measurements will be required [35]." @default.
• W2110631704 created "2016-06-24" @default.
• W2110631704 creator A5011424051 @default.
• W2110631704 date "2000-10-01" @default.
• W2110631704 modified "2023-09-27" @default.
• W2110631704 title "Serological markers of disease activity in tuberculosis and HIV infection" @default.
• W2110631704 cites W1481233402 @default.
• W2110631704 cites W1541448594 @default.
• W2110631704 cites W1626485058 @default.
• W2110631704 cites W1963713418 @default.
• W2110631704 cites W1972404798 @default.
• W2110631704 cites W1987088928 @default.
• W2110631704 cites W1995714759 @default.
• W2110631704 cites W1999300957 @default.
• W2110631704 cites W2022130131 @default.
• W2110631704 cites W2029777784 @default.
• W2110631704 cites W2045042359 @default.
• W2110631704 cites W2048287192 @default.
• W2110631704 cites W2057320667 @default.
• W2110631704 cites W2058220670 @default.
• W2110631704 cites W2062704228 @default.
• W2110631704 cites W2070073001 @default.
• W2110631704 cites W2074897557 @default.
• W2110631704 cites W2088657493 @default.
• W2110631704 cites W2097106414 @default.
• W2110631704 cites W2097655644 @default.
• W2110631704 cites W2107650053 @default.
• W2110631704 cites W2111270034 @default.
• W2110631704 cites W2129324245 @default.
• W2110631704 cites W2137852830 @default.
• W2110631704 cites W2144303909 @default.
• W2110631704 cites W2145051740 @default.
• W2110631704 cites W2151711655 @default.
• W2110631704 cites W2153978383 @default.
• W2110631704 cites W2156890490 @default.
• W2110631704 cites W2161747405 @default.
• W2110631704 cites W2168892256 @default.
• W2110631704 cites W2170211025 @default.
• W2110631704 cites W2171141994 @default.
• W2110631704 cites W2394562290 @default.
• W2110631704 cites W2414085927 @default.
• W2110631704 doi "https://doi.org/10.1046/j.1365-2249.2000.01371.x" @default.
• W2110631704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1905751" @default.
• W2110631704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11012610" @default.
• W2110631704 hasPublicationYear "2000" @default.
• W2110631704 type Work @default.
• W2110631704 sameAs 2110631704 @default.
• W2110631704 citedByCount "3" @default.
• W2110631704 countsByYear W21106317042018 @default.
• W2110631704 crossrefType "journal-article" @default.
• W2110631704 hasAuthorship W2110631704A5011424051 @default.
• W2110631704 hasBestOaLocation W21106317041 @default.
• W2110631704 hasConcept C142724271 @default.
• W2110631704 hasConcept C159047783 @default.
• W2110631704 hasConcept C159654299 @default.
• W2110631704 hasConcept C203014093 @default.
• W2110631704 hasConcept C2779134260 @default.
• W2110631704 hasConcept C2781069245 @default.
• W2110631704 hasConcept C3013748606 @default.
• W2110631704 hasConcept C45189115 @default.
• W2110631704 hasConcept C71924100 @default.
• W2110631704 hasConceptScore W2110631704C142724271 @default.
• W2110631704 hasConceptScore W2110631704C159047783 @default.
• W2110631704 hasConceptScore W2110631704C159654299 @default.
• W2110631704 hasConceptScore W2110631704C203014093 @default.
• W2110631704 hasConceptScore W2110631704C2779134260 @default.
• W2110631704 hasConceptScore W2110631704C2781069245 @default.
• W2110631704 hasConceptScore W2110631704C3013748606 @default.
• W2110631704 hasConceptScore W2110631704C45189115 @default.
• W2110631704 hasConceptScore W2110631704C71924100 @default.
• W2110631704 hasIssue "1" @default.
• W2110631704 hasLocation W21106317041 @default.
• W2110631704 hasLocation W21106317042 @default.
• W2110631704 hasLocation W21106317043 @default.
• W2110631704 hasOpenAccess W2110631704 @default.
• W2110631704 hasPrimaryLocation W21106317041 @default.
• W2110631704 hasRelatedWork W1973460911 @default.
• W2110631704 hasRelatedWork W2024428535 @default.
• W2110631704 hasRelatedWork W2096903645 @default.
• W2110631704 hasRelatedWork W2157254320 @default.
• W2110631704 hasRelatedWork W2342011470 @default.
• W2110631704 hasRelatedWork W2367214875 @default.
• W2110631704 hasRelatedWork W2412999881 @default.
• W2110631704 hasRelatedWork W2415759662 @default.
• W2110631704 hasRelatedWork W2884171184 @default.
• W2110631704 hasRelatedWork W3215265998 @default.
• W2110631704 hasVolume "122" @default.
• W2110631704 isParatext "false" @default.
• W2110631704 isRetracted "false" @default.
• W2110631704 magId "2110631704" @default.
• W2110631704 workType "article" @default.